Altimmune (NASDAQ:ALT) CFO Acquires $16,200.00 in Stock

Altimmune, Inc. (NASDAQ:ALT – Get Free Report) CFO Gregory Weaver bought 10,000 shares of the firm’s stock in a transaction on Friday, November 13th. The shares were bought at an average price of $1.62 per share, with a total value of $16,200.00. Following the completion of the purchase, the chief financial officer owned 73,005 shares in the company, valued at approximately $118,268.10. The trade was a 15.87% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Altimmune Stock Performance

Shares of NASDAQ ALT traded up $0.04 during midday trading on Friday, hitting $1.66. 3,501,696 shares of the stock traded hands, compared to its average volume of 4,245,085. The firm has a 50-day moving average of $2.62 and a two-hundred day moving average of $3.17. The firm has a market capitalization of $321.93 million, a P/E ratio of -2.12 and a beta of 0.16. The company has a debt-to-equity ratio of 0.07, a quick ratio of 26.78 and a current ratio of 26.78. Altimmune, Inc. has a one year low of $1.58 and a one year high of $6.44.

Altimmune (NASDAQ:ALT – Get Free Report) last released its quarterly earnings results on Thursday, November 12th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.02). On average, equities analysts forecast that Altimmune, Inc. will post -0.58 EPS for the current fiscal year.

Institutional Investors Weigh In On Altimmune

Several hedge funds and other institutional investors have recently modified their holdings of ALT. Dimensional Fund Advisors LP raised its holdings in Altimmune by 268.7% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,045,926 shares of the company’s stock worth $3,221,000 after purchasing an additional 762,223 shares during the period. Bank of America Corp DE lifted its position in Altimmune by 48.6% during the first quarter. Bank of America Corp DE now owns 570,203 shares of the company’s stock valued at $1,756,000 after purchasing an additional 186,420 shares in the last quarter. Bank of New York Mellon Corp purchased a new position in Altimmune during the second quarter valued at $2,097,000. Squarepoint Ops LLC grew its holdings in Altimmune by 1,016.5% during the second quarter. Squarepoint Ops LLC now owns 202,380 shares of the company’s stock valued at $615,000 after purchasing an additional 184,254 shares during the period. Finally, Wellington Management Group LLP grew its holdings in Altimmune by 69.4% during the second quarter. Wellington Management Group LLP now owns 420,300 shares of the company’s stock valued at $1,278,000 after purchasing an additional 172,142 shares during the period. 78.05% of the stock is currently owned by hedge funds and other institutional investors.

Recent Altimmune Headlines

These are some of the ALT headlines that stood out recently:

  • Positive Sentiment: New 48-week Phase 2b IMPACT data showed significant improvements in measures of liver fat, inflammation and fibrosis, alongside weight loss and generally favorable tolerability for investigational pemvidutide in MASH. The results were published in The Lancet Gastroenterology & Hepatology and support the ongoing Phase 3 PERFORMA trial. Article
  • Positive Sentiment: Altimmune reported $480 million in cash, cash equivalents and investments at September 30, with a stated runway through the PERFORMA readout and into 2029—an important buffer for its clinical programs. Article
  • Negative Sentiment: Third-quarter loss per share was $0.15, wider than the $0.13 consensus estimate. Higher research and development costs are pressuring results, and investors remain focused on the capital required to advance the pipeline despite the reported cash runway. Article

Analyst Ratings Changes

Several brokerages have issued reports on ALT. Citigroup reissued a “market outperform” rating on shares of Altimmune in a research report on Friday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Altimmune in a research report on Monday, September 21st. HC Wainwright reaffirmed a “buy” rating on shares of Altimmune in a research report on Tuesday, July 28th. B. Riley Financial reiterated a “buy” rating on shares of Altimmune in a research note on Friday. Finally, Evercore reissued an “outperform” rating on shares of Altimmune in a report on Wednesday, September 23rd. Eight equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Altimmune currently has an average rating of “Moderate Buy” and an average target price of $14.33.

View Our Latest Research Report on ALT

About Altimmune

(Get Free Report)

Altimmune, Inc. is a clinical-stage biopharmaceutical company developing peptide-based treatments for obesity and liver diseases. The company is headquartered in Gaithersburg, Maryland. Its lead candidate, pemvidutide, is an investigational medicine that activates GLP-1 and glucagon receptors. Altimmune has studied the drug for obesity and metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease. Altimmune’s work focuses on advancing treatments through clinical development; pemvidutide is not an approved medicine.

Read More

Insider Buying and Selling by Quarter for Altimmune (NASDAQ:ALT)

Receive News & Ratings for Altimmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Altimmune and related companies with MarketBeat.com's FREE daily email newsletter.